MKC8866
CAS No. 1338934-59-0
MKC8866 ( —— )
Catalog No. M23496 CAS No. 1338934-59-0
MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29?μM in human vitro).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 177 | In Stock |
|
10MG | 288 | In Stock |
|
25MG | 484 | In Stock |
|
50MG | 701 | In Stock |
|
100MG | 981 | In Stock |
|
500MG | 1962 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMKC8866
-
NoteResearch use only, not for human use.
-
Brief DescriptionMKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29?μM in human vitro).
-
DescriptionMKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29?μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorIRE1 RNase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1338934-59-0
-
Formula Weight361.4
-
Molecular FormulaC18H19NO7
-
Purity>98% (HPLC)
-
SolubilityDMSO:16.67 mg/mL (46.13 mM; Need ultrasonic)
-
SMILESO=CC1=C(O)C(OC)=CC2=C1OC(C(CC(N3CCOCC3)=O)=C2C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sheng X, et al. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019 Jan 24;10(1):323.
molnova catalog
related products
-
Desoxo-narchinol A
Desoxo-narchinol A exhibits protective effects against LPS-induced endotoxin shock and inflammation through p38 deactivation, it shows inhibitory activity against LPS-induced NO production. Desoxo-narchinol A shows cytotoxic activity against P-388 cells.
-
Magnoloside B
The barks of Magnolia obovata.
-
N-Succinimidyl 4-(N-...
N-Succinimidyl 4-(N-maleimidomethyl)cycl(SMCC) also known as succinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate is a heterobifunctional protein crosslinker.